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We have reported previously on the generation of a mono-
clonal antibody against human macrophage migration in-
hibitory factor (MIF), which is a mediator of cellular im-
munity . Macrophage migration inhibitory factor activity 
in the migration assay was closely correlated with antibody 
reactivity. Using this antibody called lC5/B, we are now 
a ble to study the expression of MIF in situ. Here, we report 
on the detection of MIF in blood lymphocytes and skin of 
a patient with a leukemic cutaneous T-cell lymphoma with 
the characteristics of Sezary syndrome. Ninety percent of 
the patient's Ficoll Hypaque-isolated peripheral white blood 
cells were of the helper phenotype. By conventional im-
munoperoxidase method, 94% reacted strongly positive 
M acrophage migration inhibitory facto r (MIF) was the first Iymphokine to be described and was defined by its inhibitory effect on the migration . of macro phages from capillary tubes [1). Its re-lease by cultured mononuclear cells upon antigen 
stimulation has been considered to be an equivalent to the state 
of hypersensitivity in vivo. Relatively little information is avail-
able on the production of MIF in vivo and its relation to the 
physiology and pathology of inflammatory reactions . An MIF-
like activity was previously detected in the serum of animals 
which had been infected with bacillus Cal mette-Guerin and of 
patients with sarcoidosis, leprosy , and Sezary syndrome, a leu-
kemic T -cell lymphoma of helper cell type [2-5) . However, in-
formation on the distribution and function ofMIF in the organism 
is lacking. Recently this molecule has been characterized and has 
been shown to exert profound effects on macrophage differen-
tiation [6,7]. From in vitro experiments it is generally concluded 
that MIF is produced by T cells when they are stimulated either 
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with the antibody lC5/B. In contrast, using the immu-
nofluorescence method only 25% reacted positive. This 
indicates that the majority of the tumor cells did not express 
the molecule on their membrane but only in the cyto-
plasma. No other marker, such as interleukin 2 receptor, 
HLA-DR antigen, or interferon-gamma could be related 
to the expression of MIF. Also the cellular infiltrate in the 
skin was composed mainly of T helper cells and reacted 
positive with lC5/B. As less than 3% of normal blood 
lymphocytes reacted with lC5/B we suggest that the con-
version to positivity may be a characteristic feature of the 
leukemic T-cell phenotype in Sezary syndrome. ] Invest 
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by antigen or mitogen [1). Direct identification of the cells that 
contain MIF has now become possible by a monoclonal antibody, 
which we prepared against highly puri"fied MIF from mitogen-
stimulated human peripheral blood mononuclear cells [8] . We 
show here that the malignant T cells of a patient with a leukemic 
cutaneous T-cell lymphoma (CTCL) of the helper type express 
MIF-related structures. 
MATERIALS AND METHODS 
Case History A 51-year-old woman with a 2-year history of 
erythroderma and grossly enJarged axillary and groin lymph nodes 
showed rising peripheral white blood cell counts some months 
before the investigation. At the time of investigation the total 
white cell count was 56,0001 ILl, a differential blood count showed 
70% lymphocytes, 2% eosinophils, 2% monocytes, and 16% 
neutrophils . Most lymphocytes appeared atypical, being larger 
than normal with prominent nucleoli and approximately 20% 
had a highly indented nucleus. Lactate dehydrogenase in the serum 
was strongly elevated (900 units/ml). Anti-HTLV-I, -II antibod-
ies, as evaluated by an enzyme-linked immunosorbent assay were 
negative. The examination of an enlarged lymph node of the groin 
(Prof. Dr. K . Lennert, Kiel, F.R.G.) revealed a T -zone lym-
phoma, in agreement with a Sezary syndrome. By ultrasound 
investigation abdominal lymph nodes, spleen, and liver were found 
to be normal. A bone marrow smear showed no infiltration with 
malignant cells at the time of investigation . 
Blood Cells Lymphoid cells were isolated from heparinized 
blood by Ficoll Hypaque centrifugation (Pharmacia , Uppsala, 
Sweden) and used for preparation of semi thin sections, cytocen-
trifuge smears, and for flow cytofluorometry with an EPICS V 
(Coulter Electronics, Inc. , Hialeah , Florida). The percentage of 
cells that were labeled positive by indirect immunofluorescence 
technique was calculated by the Immuno Software supplied by 
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Figure 1. Semithin section of Ficoll Hypaque-isolated peripheral blood 
cells. M a ny cells show highly convoluted nuclei and heterochromatin 
attached to their nuclear membrane. Bar = 10 p.m. Counterstain: Meyer's 
haema la un . 
Coulter. For semi thin sections the cell button was fixed with 
glutaraldehyde (4%). 
Antibodies M onoclonal antibodies diluted as indicated in the 
specification sheets of the suppliers were used: Leu 3a, Leu 4, 
anti-interleukin 2 (lL-2) receptor (Becton Dickinson, Heidelberg, 
F.R. G . ); anti-interferon-gamma (lFN-I') , (code 2067, Cell tech , 
GB), T4, TS, T6 (Coulter C lone, Krefeld , F.R.G .); Ki67 (pro-
liferation marker) (Dakopatts, Hamburg, F.R.G.); OKM1, OKM5 
(Ortho Diagnostics, H amburg, F.R.G.); and D-1-12 for detection 
ofHLA- DR antigen (kindly provided by Dr. S. Carrel, Lausanne, 
Switze rland). Production procedure and characteriza tion of the 
monoclonal antibody 1 C5 aga inst human MIF were described 
elsewhere [S]. Briefly, the antibody was generated against a 14 
kD species of MIF from human peripheral blood mononuclea r 
cells a nd binds but does not neutralize MIF [8]. T he antibody was 
biotiny l ated according to Guesdon et al [9J and diluted 1: 400. 
Skin Six-millimeter punch biopsies were taken from the fo re-
arm a nd either fixed in bu ffe red formalin for routine hi stologic 
investigatio n or snap-frozen in liquid nitrogen for immunola-
beling. 
Inununoperoxidase Technique Six-micrometer frozen skin 
sections were air-dried with acetone (10 min) and preincubated 
with 0.1% hyd rogen peroxide and 1 % bovine serum albumin. 
Incubation with the relevant antibody was performed fo r 45 min 
at raoUl temperature. Secondary to the commercial antibodies 
peroxidase-conjugated goat antimouse IgG F(ab'h (Dianova, 
Figure 2 . Cytoccntrifugc prcparations of Ficoll Hypaquc-isolatcd pe-
ripheral blood ce lls from the patient. Bars = 30 p.m. Counters tain: Meyers 
haen~a l a un . A , Leukemic tumor cel ls stain positive fo r MIF with the 
ICS/B a ntibody. Monocytes are negative at the employed dilution of 
anti body. B, Leukemic tumor cells stain also positi ve with Leu 3a anti-
body, characterizing thcm as T helper cells. 
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Table I. Percent Mononuclea r Peripheral Blood Cell s" From 
Cytocentri fuge Preparations T hat Stained Positive 
by Immunoperoxidase 
T4 T8 Leu 4 IC5 B Ki67 IL-2-rec IFN-1' D-I-12 
90 2 93 94 12 8 
' Prepared by Ficoll Hypaq ue, 200 cells were eva luated by the microscope. 
Table II . Percent Mononuclear Peripheral Blood Cells T hat 
Stained Positive as D etected by EPIC S va Analysis 
T4 Leu 4 lC5 B IL-2-rec 
94 88 25 o 
' Mononuclea r cells were prepared by Ficoll H ypaquc, 30,000 cell s were analyzed . 
Hamburg, F.R.G.) was applied for 30 min at room temperature. 
Secondary to the biotinylated 1 C5/B antibody peroxidase-co n-
jugated Streptaviclin (Amersham, Braunschweig, F. R. G.) was used. 
All antibod ies were dilu ted with phosphate-buffered saline, con-
taining 1 % bovine serum albumin . Peroxidase activity was dem-
onstrated w ith the 3-amino-9-ethylcarbazole reaction [10] . T he 
preparations were counterstained with Meyer's haem alaun (Merck, 
Darmstadt , F.RG.). 
RESULTS 
Blood Semithin sections of Ficoll H ypaque preparations from 
the peripheral blood of the patient revealed m any atypi cal lym-
phocytes displaying characteristic features of CTCL (Fig 1). 
Figure 2A depicts cells from cytocentrifu ge smears that stained 
strongly positive for MIF and Fig 2B shows that the cells display 
the T helper phenotype. Monocytes stained negative with 1 C5/B 
at the employed concentrations . Controls using biotinylated mOllse 
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Forward angle light scatter 
Figure 3. Distribution of membrane-labeled cells according to their flu-
orcscence intensity and size as measured by fo reward angle light scattcr. 
3A shows thc resul ts with Leu 4 antibody, 3A 1 the corresponding control 
with mouse IgG. 3B shows the rcsults with l C51B antibody, 3B1 thc 
co rresponding control with biotinylated mouse IgG . A 'TOI I' S indicate ac-
cumulation of cclls that stain posi tive above background. It can be secn 
that peaks of Leu 4-positive cells and 1 C51B-positive cells do not overlap. 
This indicates that large Lcu 4-positive cells do not express MIF on their 
mcmbranc. 
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Figure 4. Skin sections. Counterstain: Mcycrs haemalaun. A, The dermal 
infil t rate stai ns st rongly posi tive with the pan T -cell marker Leu 4, (Bm' 
= 30 J,Lm) . B, T he same areas of the dermis sta in strongly positi ve for 
MIF w ith 1CS/B (Bar = 30 J,Lm). C , MIF-positi ve, morphologica ll y 
highly atypica l cel ls arC clearly visib le in the densely infiltrated upper 
dermis on higher magnifi cation (B(/r = 10 J,Lm). D, In the dermal infiltrate 
onl y very few cel ls stain positive with an an tibody to IFN-y (see ar/"Ow-
heads) (Bar = 20 J,Lm ). 
IgG and Streptavidin were constantl y negative. In cytocentrifu ge 
preparation from hea lth y cont rols onl y vcry few lymphocytes 
sta ined positive (:53%) . 
Table I shows the percentage of mononuclear cells from cy-
tocentrifuge preparations that stained positive w ith various o ther 
an tibod ies. Ninety percent of the cells were T cells w ith the helper 
phenotype (T4/Leu 3a), w hich is a typica l fi ndin g for the Sezary 
syndrome [11] . Ninety-fo ur percent stai ned positive for MIF w ith 
1C5/B. In contrast, IFN-y as well as the IL-2 recepto rs and HLA-
DR antigens D-1-1 2, which are activation markers, were not 
expressed. T he absence ofIL-2 receptors on th e circulating tumor 
cells together with the absence of antibodies to human T Iym-
photropic virus (HTL V) I and HTL V II clearly distinguished this 
case from the Japanese form of ad ult T-cell leukemia [12]. Twelve 
percent of the cells were in the cell cycle as revea led by posi tive 
staining with the Ki67 an tibody. Others have reported that Sezary 
cells in the blood are not cycl in g [13] . This discrepancy is probably 
explained by the aggressive course that the disease took at the 
time of investigat ion, since hepatosplenomegaly and bone mar-
row infiltration occurred 3 months later. 
An immunoflu o rescence test was don e to defin e more precisely 
the cellular loca lization of the M[F epitope. Table II shows the 
percentage of monon uclea r peripheral blood cells with posi tive 
membrane flu o rescence as revea led by EPICS V. Again , a high 
percentage (94%) were positive with the T helper cell marker 
(T4), indicating its localiza tion on the cell membrane. [n contrast, 
only 25% showed membrane fluorescence with lC5/B. Com-
paring this result to the numbers of cells that stained positive by 
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imm un operoxidase, it beco mes apparent that MIF was mainl y 
loca ted in the cytopb sma of the cell s. 
Figure 3 shows the distribution of the pati ent 's ce ll s accordin g 
to their size as measured by forward angle light sca tter and mem-
bra n e fluorescence intensity usin g the 1 C5/B antibody and the 
pan T - cel l marker Leu 4. It can be seen that large Leu 4-positi ve 
cells did not express MIF on their membrane. From their size, 
those cells that did ex press MIF on their membranes resembled 
normal I ym phocytes. 
Skin 
Histo l ogy: Slides sta in ed w ith hematoxylin-eosin showed thick-
ened epidermis with elonga ted rete ridges and a dense, band-like 
infi ltrate with nodu lar accentuation in the upper dermis. The 
in fi ltra te extended into the papill ary tips with so me exocytosis 
into the epidermis. The Iy m phocytes were larger than no rmal , 
many h ad a blast-like appearan ce, others showed highl y convo-
luted nu clei, consis tent with the diagnosis of CTCL. 
1I/IIIIuI1 operoxidase Srnillillg: The infiltrate was mainl y co mposed 
ofT lyrn.phocy tes (Fig 4A), w hich alm os t excl usively ca rried the 
T 4/Leu 3a marker for T helper cells co rrespondin g to the findings 
in the periphera l blood . The dermal T cells stained pos itive with 
anti-HLA-DR antibody, accordin g to what is known about ma-
lignant T cells infiltrating the skin [1 4]. There was a moderate 
migration of these cell s into the epidermis. In the center of the 
densel y infiltrated areas so me dendritic cells stained positi ve with 
T6 and probably represented Langerhans cells. In the sa me area 
man y lynlphoid cells expressed the IL-2 receptor as detected by 
anti-Tac, indi cating that they had beco me activated in the dermis 
[IS]. M acrophages as detected by OKM1 and OKM5 were mod-
era tely scattered throughout the derm is. Many cell s in the dermis 
sta ined positive w ith l C5/B even at high dilutions (Fig 48, C) . 
Quan tit y and pattern of distribution was similar to th e atypi ca l 
Leu 4-positive cells. Controls, including Streptavidin and bioti-
ny lated mouse IgG, we re negati ve. Twenty to thirty percent of 
the infiltrating cells were cycling as they stain ed positive with 
Ki67. SOl"ne cells migratin g into the epidermis were positive with 
ICS/B. In co ntrast, the antibody aga inst IFN-I' detected only 
very fevv cells in the derma l infiltrates (Fig 4D). 
D ISC U SSIO N 
Usin g a monoclona l antibody to MIF we found th at circulating 
and skin-associated leukemic T cells in a patient w ith advanced 
Sezary syndrome reacted posit ive. This findin g is of interest be-
cause so fa r MIF-like activity has been detected onl y in the serum 
of th ese patients and in the culture supern atants of peripheral 
bloo d n, o no nuclear ce lls [5]. We ca nnot decide from our res ults 
whether MIF is acti vely secreted by th e tumor cells o r re leased 
upon cell d ea th . The work on the characteriza tion of the antibody 
shows that the l C5 epitope most likely indicates the presence of 
MIF ~olecules . When m onito ring various separation procedures, 
the binding curves with 1 C5/B antibody overlap qualitatively and 
quantitativel y with those of MIF act ivity as measured by the 
migratio n assay [8]. Definite proof, however, for MIF production 
by the patient's tum or cells would be the detection of messenger 
RNA in the cy to plasma of the cell s. 
Besides the high pro portion of circulating leukemic T cells that 
showed cytoplas mic stainin g, there was also a cohort of small T 
cells , vv h i e h in addition had M IF on their mem brane surface. As 
monoeytes clearly stained nega ti ve at the antibod y cO I~ centrat ion s 
used, passive adso rption of MIF to the cell membrane is unlikel y. 
Except for T-cell markers, other membrane antigens that may be 
found on activated T cells were negative. The absence of IL-2 
receptors and HLA-DR antigens on circulating tum or cel ls dis-
tinguishes the Sezary syndro m e from the acute ad ult T - cell leu-
kem ia [1 2 ]. 
[n lyu1.phoid orga ns and periphera l blood of no rm al control 
persons on ly very fcw Iymphocytcs have been found to stain 
positive vvith 1 C5/B (G. Zwadlo et aI, unpublished; G. Gerhards 
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et aI, unpublished) . In contras t, in th e elicitation phase of contact 
eczema many of the lymphocytes in fi ltrating thc skin are MIF-
positi ve (c. N eum ann et aI, unpublished). Thus, it may be that 
MIF is preferentially expressed by a distinct subpopulation that 
has a marked propensity to infiltrate the sk in. It may further be 
specul ated that it is this MIF-positive subpopulation that expands 
in the Sezary sy nd rome. This hypothesis secms in triguing, as it 
is in creasin gly recognized that the skin possesscs various impor-
tant immune mechanisms [1 6,17]. In two further cases of eryth-
rodermic CTCL but without leukemia we have also found a 
signifi cant propo rti on of MIF-positive cells in the dcrmal inftl-
trate. In these nonleukcmic cases , however, the peripheral blood 
contained on ly a few MIF-positive cclls. Blastogenic leukemia in 
CTCL as seen in the patient presented here is an extremel y ra re, 
late event in the course of the disease. Further cases have to clarify 
w hether the appeara nce of MIF-positive tumor cells in the blood 
is typical for the leukemic stage of the disease. 
The fun ctional signifi cance of MI F in CTCL is no t clear. As 
MIF has profound effects on the differentiation of m ononuclear 
phagocytes, it appears appropriate to investiga te this cell sys tem 
in paticnts w ith incrcased MIF expression. Others have sugges ted 
that MIF can abrogate cellular immune reactions 11 8]. Whether 
the immunosuppression that is seen in patients with CTCL can 
be related to MIF rem ains to be inves tiga ted. 
We also investigated IFN-I' because it is another prod uct of 
activated T-cell subsets [1 9]. In contrast to MIF, thc blood cells 
of our patient did not stain positive w ith an antibody against IFN-
I' and accordin gly the dermal infiltrate was almost ncgative. T his 
might be surprisin g since IFN-I' is sccreted upon antigenic stim-
ulation and one of thc proposed etio logic facto rs of CTCL is 
chronic antigenic stimulati on of T cells in the sk in [20]. O n the 
o ther hand , the negativity for IFN-I' might have resulted from 
functional defects of the m alignant T cells, w hich undoubtedl y 
m ay occur in C T CL [21]. 
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